For instance, the JMJD5 inhibition assays reveal that the PHD inhibitor roxadustat, which is the active pharmaceutical ingredient of a human chemotherapeutic used to treat chronic kidney disease-associated anemia,63,67 does not inhibit JMJD5 at substantial levels (Table 5, entry ix). This evidence concerns the gene PDC and anemia (phenotype).